Gadofosveset
Gadofosveset is a gadolinium-based [MRI contrast agent]. It was used as the trisodium salt monohydrate form. It acts as a blood [pool agent] by binding to human serum albumin. The manufacturer discontinued production in 2017 due to poor sales.
Gadofosveset consists of a gadolinium cation bound to the chelating agent fosveset. It facilitates high-resolution magnetic [resonance angiography]. Ferumoxytol, an intravenous iron-replacement therapy, has been shown to potentially be superior to gadofosveset as a blood pool agent for MR venography in pediatric patients.